Zhang Shumin M, Cook Nancy R, Albert Christine M, Gaziano J Michael, Buring Julie E, Manson Joann E
Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
JAMA. 2008 Nov 5;300(17):2012-21. doi: 10.1001/jama.2008.555.
Folate, vitamin B(6), and vitamin B(12) are thought to play an important role in cancer prevention.
To evaluate the effect of combined folic acid, vitamin B(6), and vitamin B(12) treatment on cancer risk in women at high risk for cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS: In the Women's Antioxidant and Folic Acid Cardiovascular Study, 5442 US female health professionals aged 42 years or older, with preexisting cardiovascular disease or 3 or more coronary risk factors, were randomly assigned to receive either a daily combination of folic acid, vitamin B(6), and vitamin B(12) or a matching placebo. They were treated for 7.3 years from April 1998 through July 31, 2005.
Daily supplementation of a combination of 2.5 mg of folic acid, 50 mg of vitamin B(6), and 1 mg of vitamin B(12) (n = 2721) or placebo (n = 2721).
Confirmed newly diagnosed total invasive cancer or breast cancer.
A total of 379 women developed invasive cancer (187 in the active treatment group and 192 in the placebo group). Compared with placebo, women receiving the active treatment had similar risk of developing total invasive cancer (101.1/10,000 person-years for the active treatment group vs 104.3/10,000 person-years for placebo group; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.79-1.18; P = .75), breast cancer (37.8/10,000 person-years vs 45.6/10,000 person-years, respectively; HR, 0.83; 95% CI, 0.60-1.14; P = .24), or any cancer death (24.6/10,000 person-years vs 30.1/10,000 person-years, respectively; HR, 0.82; 95% CI, 0.56-1.21; P = .32).
Combined folic acid, vitamin B(6), and vitamin B(12) treatment had no significant effect on overall risk of total invasive cancer or breast cancer among women during the folic acid fortification era.
clinicaltrials.gov Identifier: NCT00000541.
叶酸、维生素B6和维生素B12被认为在癌症预防中发挥重要作用。
评估联合使用叶酸、维生素B6和维生素B12治疗对心血管疾病高危女性患癌风险的影响。
设计、地点和参与者:在女性抗氧化剂和叶酸心血管研究中,5442名年龄在42岁及以上、患有心血管疾病或有3种及以上冠心病危险因素的美国女性健康专业人员被随机分配接受每日联合服用叶酸、维生素B6和维生素B12或匹配的安慰剂。她们从1998年4月至2005年7月31日接受了7.3年的治疗。
每日补充2.5毫克叶酸、50毫克维生素B6和1毫克维生素B12的组合(n = 2721)或安慰剂(n = 2721)。
确诊的新诊断侵袭性癌症或乳腺癌。
共有379名女性患侵袭性癌症(活性治疗组187例,安慰剂组192例)。与安慰剂相比,接受活性治疗的女性患侵袭性癌症的总体风险相似(活性治疗组为101.1/10000人年,安慰剂组为104.3/10000人年;风险比[HR],0.97;95%置信区间[CI],0.79 - 1.18;P = 0.75),患乳腺癌的风险相似(分别为37.8/10000人年和45.6/10000人年;HR,0.83;95% CI,0.60 - 1.14;P = 0.24),或任何癌症死亡风险相似(分别为24.6/10000人年和30.1/10000人年;HR,0.82;95% CI,0.56 - 1.21;P = 0.32)。
在叶酸强化时代,联合使用叶酸、维生素B6和维生素B12治疗对女性侵袭性癌症或乳腺癌的总体风险没有显著影响。
clinicaltrials.gov标识符:NCT00000541。